MaltSci 麦伴科研

Appearance

Curated Papers > Recent high-impact research on "Alzheimer's Disease" (IF≥30, past 5 years)

Cervical cancer prevention and control in women living with human immunodeficiency virus. ​

Literature Information ​

DOI10.3322/caac.21696
PMID34499351
JournalCA: a cancer journal for clinicians
Impact Factor232.4
JCR QuartileQ1
Publication Year2021
Times Cited92
KeywordsAfrica, cervical cancer, cytology, human immunodeficiency virus (HIV), human papillomavirus (HPV)
Literature TypeJournal Article, Research Support, N.I.H., Extramural, Review
ISSN0007-9235
Pages505-526
Issue71(6)
AuthorsPhilip E Castle, Mark H Einstein, Vikrant V Sahasrabuddhe

TL;DR ​

Cervical cancer remains a leading cause of cancer-related morbidity and mortality among women, particularly in low-income countries and among those living with HIV, who have a significantly heightened risk due to compromised immune responses to human papillomavirus. This study critically evaluates the relationship between HIV and cervical cancer, highlighting the need for integrated prevention and control efforts to reduce cervical cancer incidence and promote public health globally.

Search for more papers on MaltSci.com ​

Africa · cervical cancer · cytology · human immunodeficiency virus (HIV) · human papillomavirus (HPV)

Abstract ​

Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer is often the leading cause of cancer-related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub-Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem.

MaltSci.com AI Research Service ​

Intelligent ReadingAnswer any question about the paper and explain complex charts and formulas
Locate StatementsFind traces of a specific claim within the paper
Add to KBasePerform data extraction, report drafting, and advanced knowledge mining

Primary Questions Addressed ​

  1. What specific strategies can be implemented to improve cervical cancer screening among women living with HIV?
  2. How does the immune response in women with HIV affect the progression of HPV infections and subsequent cervical cancer development?
  3. What are the barriers to integrating cervical cancer prevention programs into existing HIV care frameworks in low-income countries?
  4. How can public health campaigns be tailored to raise awareness about the increased cervical cancer risk among women living with HIV?
  5. What role do vaccines against HPV play in the prevention of cervical cancer for women with compromised immune systems, such as those living with HIV?

Key Findings ​

Background and Objectives ​

Cervical cancer remains a significant global health issue, particularly among women living with HIV (WLWH), who face heightened risks due to immune system impairment. This article critically evaluates the intersection of HIV and cervical cancer, emphasizing the need for integrated prevention and control strategies. The primary objective is to analyze existing evidence regarding cervical cancer risk in WLWH and to propose enhanced methods for screening and treatment.

Methods/Materials/Experimental Design ​

The authors employed a comprehensive literature review approach, analyzing data from various studies, including meta-analyses, cohort studies, and epidemiological data. They focused on the following key areas:

  1. Epidemiology of Cervical Cancer in WLWH: Assessment of cervical cancer incidence and mortality rates in different geographical regions, particularly in low- and middle-income countries (LMICs).
  2. HPV and HIV Interactions: Examination of how HIV affects the natural history of HPV infection and cervical cancer progression.
  3. Prevention Strategies: Discussion on primary (HPV vaccination) and secondary (cervical screening) prevention methods, particularly in resource-limited settings.

The methodological framework can be represented as follows:

Mermaid diagram

Key Results and Findings ​

  1. Cervical Cancer Burden: The incidence of cervical cancer in WLWH is significantly higher compared to HIV-negative women, with estimates showing a sixfold increase in risk.
  2. HIV Impact: HIV infection is associated with higher rates of HPV acquisition and persistence, which increases the likelihood of developing cervical precancerous lesions and invasive cancer.
  3. Prevention Efficacy: Prophylactic HPV vaccination has shown promise in reducing cervical cancer risk, but its effectiveness may vary based on HIV status and treatment adherence.
  4. Screening Recommendations: The article advocates for more frequent cervical screening for WLWH, recommending HPV testing as the primary screening method, particularly every 3 to 5 years for women aged 25 to 49.

Conclusions/Significance/Innovation ​

The authors conclude that integrating HIV care with cervical cancer prevention strategies can significantly reduce the burden of cervical cancer among WLWH. The dual approach of improving HIV management and enhancing cervical cancer screening and vaccination programs is crucial. This integration is particularly vital in LMICs, where resources are limited, and the burden of disease is highest. The findings underscore the need for tailored public health strategies that address both HIV and cervical cancer simultaneously.

Limitations and Future Directions ​

  1. Study Limitations: The authors note the variability in data quality and availability across different regions, which may affect the generalizability of findings.
  2. Future Research: There is a need for longitudinal studies to assess the long-term efficacy of HPV vaccination in WLWH and to optimize screening protocols tailored to this population. Additionally, exploring the socio-economic barriers to accessing preventive care in LMICs will be essential for developing effective interventions.

In summary, the article emphasizes the critical intersection of HIV and cervical cancer, advocating for integrated prevention strategies that can significantly improve outcomes for WLWH globally.

References ​

  1. Update of Survival for Persons With HIV Infection in Denmark. - Nicolai Lohse;Niels Obel - Annals of internal medicine (2016)
  2. WHO Launches Global Push to Eliminate Cervical Cancer. - Bridget M Kuehn - JAMA (2021)
  3. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. - Elissa Meites;Allison Kempe;Lauri E Markowitz - MMWR. Morbidity and mortality weekly report (2016)
  4. Telementoring in gynecologic oncology training: changing lives in Mozambique. - Renato Moretti-Marques;Mila Pontremoli Salcedo;Donato Callegaro Filho;Andre Lopes;Marcelo Vieira;Geórgia Fontes Cintra;Magda Ribeiro;Dércia Changule;Siro Daud;Ricardina Rangeiro;Ellen Baker;Cesaltina Lorenzoni;Jose Humberto Tavares Guerreiro Fregnani;Kathleen M Schmeler - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
  5. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. - Susanne K Kjær;Kirsten Frederiksen;Christian Munk;Thomas Iftner - Journal of the National Cancer Institute (2010)
  6. Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: a 20-year systematic review. - Jude Ogechukwu Okoye;Chukwudi Amaechi Ofodile;Oluwaseun Kelechi Adeleke;Okechi Obioma - Epidemiology and health (2021)
  7. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. - Helen Kelly;Helen A Weiss;Yolanda Benavente;Silvia de Sanjose;Philippe Mayaud; - The lancet. HIV (2018)
  8. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. - Marc Arbyn;Sara B Smith;Sarah Temin;Farhana Sultana;Philip Castle; - BMJ (Clinical research ed.) (2018)
  9. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. - Aimée R Kreimer;Joshua N Sampson;Carolina Porras;John T Schiller;Troy Kemp;Rolando Herrero;Sarah Wagner;Joseph Boland;John Schussler;Douglas R Lowy;Stephen Chanock;David Roberson;Mónica S Sierra;Sabrina H Tsang;Mark Schiffman;Ana Cecilia Rodriguez;Bernal Cortes;Mitchell H Gail;Allan Hildesheim;Paula Gonzalez;Ligia A Pinto; - Journal of the National Cancer Institute (2020)
  10. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. - Silvia de Sanjose;Cosette M Wheeler;Wim G V Quint;William C Hunt;Nancy E Joste;Laia Alemany;F Xavier Bosch; ;Evan R Myers;Philip E Castle - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2013)

Literatures Citing This Work ​

  1. Cervical cancer prevention and control in women living with human immunodeficiency virus. - Philip E Castle;Mark H Einstein;Vikrant V Sahasrabuddhe - CA: a cancer journal for clinicians (2021)
  2. Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis. - Jianying Yi;Zhili Liu;Lu Wang;Xingxin Zhang;Lili Pi;Chunlei Zhou;Hong Mu - Frontiers in oncology (2022)
  3. Development and Validation of a Nomogram for Predicting Postoperative Distant Metastasis in Patients with Cervical Cancer. - Weihong Zeng;Lishan Huang;Haihong Lin;Ru Pan;Haochang Liu;Jizhong Wen;Ye Liang;Haikun Yang - Medical science monitor : international medical journal of experimental and clinical research (2022)
  4. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. - Lili Song;Shikai Liu;Sufen Zhao - Bioengineered (2022)
  5. Update on the Epidemiological Features and Clinical Implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) Coinfection. - Alexandre Pérez-González;Edward Cachay;Antonio Ocampo;Eva Poveda - Microorganisms (2022)
  6. The Modeling Analysis and Effect of CHI3L1 and CD31-Marked Microvessel Density in the Occurrence and Development of Cervical Squamous Cell Carcinoma. - Yanzi Qin;Wenjun Zhao - Computational and mathematical methods in medicine (2022)
  7. It Takes Two to Tango: A Review of Oncogenic Virus and Host Microbiome Associated Inflammation in Head and Neck Cancer. - Mallory G McKeon;Jean-Nicolas Gallant;Young J Kim;Suman R Das - Cancers (2022)
  8. Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer. - Kui Yao;Heng Zheng;Tao Li - Frontiers in oncology (2022)
  9. Prognosis Analysis and Validation of Fatty Acid Metabolism-Related lncRNAs and Tumor Immune Microenvironment in Cervical Cancer. - Xiaolin Lang;Changchang Huang;Hongyin Cui - Journal of immunology research (2022)
  10. Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol. - Gad Murenzi;Fabienne Shumbusho;Natasha Hansen;Athanase Munyaneza;Julia C Gage;Benjamin Muhoza;Faustin Kanyabwisha;Amanda Pierz;Patrick Tuyisenge;Kathryn Anastos;Philip E Castle - BMJ open (2022)

... (82 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology